サンプル依頼リスト カート
表紙：分子ポイントオブケア（mPOC）市場：市場の見通しとイノベーション（2024年～2029年）
市場調査レポート
商品コード
1669754

分子ポイントオブケア（mPOC）市場：市場の見通しとイノベーション（2024年～2029年）

Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029

出版日
ページ情報
英文 140 Pages
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.84円
分子ポイントオブケア（mPOC）市場：市場の見通しとイノベーション（2024年～2029年）
出版日: 2025年03月06日
発行: Kalorama Information
ページ情報: 英文 140 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

分子ポイントオブケア（mPOC）診断は、従来のポイントオブケア（POC）ソリューションのアクセシビリティとスピードで、分子検査の感度と特異性を提供し、体外診断（IVD）の状況に革命をもたらしています。

mPOCは新たな技術革新から主要な市場勢力へと変遷しており、その原動力となっているのは、救命救急病棟、外来診療所、医院、地域医療の現場における迅速かつ正確な診断ソリューションに対する需要の高まりです。COVID-19パンデミックは、特に呼吸器検査分野での採用を加速させましたが、市場は院内感染（HAI）、性感染症（STI）、熱帯病など新たな分野への拡大を続けています。

当レポートでは、分子ポイントオブケア（mPOC）市場について調査し、急速に発展するこの市場を包括的に分析し、2029年までの5年間に予測される市場規模、成長見通し、競合力情勢などを網羅しています。

目次

第1章 エグゼクティブサマリー

第2章 分子ポイントオブケア市場開拓と動向

  • COVID-19と分子POC
  • 規制の動向
  • コンソーシアム、資金、賞
  • お買い得情報
  • 分子ポイントオブケアの利点と欠点
  • 根拠：感度/特異性の議論
  • 新システムとメニューの拡張
  • mPOCシステムへの取引、投資
  • POC市場としての中国
  • POC診断における一般的な検査と分析対象
  • 分子ポイントオブケア診断の要素技術
    • マイクロ流体
    • 定量PCR
    • マイクロアレイ
    • 等温増幅
    • テスト自動化
    • プライマーとプローブ
    • 検出
    • 次世代シーケンシング
    • 分子診断
    • リアルタイムPCR（qPCR）
    • 等温増幅法
    • ループ介在等温増幅（LAMP）
    • ニッキング酵素増幅反応（NEAR）
    • 鎖置換増幅（SDA）
    • ヘリカーゼ依存性増幅（HDA）
    • 核酸配列に基づく増幅（NASBA）
    • 転写介在増幅（TMA）
    • クロスプライミング増幅（CPA）
    • ラインプローブアッセイ
  • 分子ポイントオブケアの用途と潜在的用途
    • 分子POC診断の主な試験
    • インフルエンザ
    • RIDTの再分類
    • 院内感染（HAI）
    • 連鎖球菌A
    • 呼吸器合胞体ウイルス（RSV）
    • 新たな用途
    • ジカ熱
    • その他の呼吸器感染症
    • B群連鎖球菌
    • ヒトパピローマウイルス
    • 単純ヘルペスウイルス
    • 膣炎
    • 結核
    • マラリア
    • その他の熱帯および無視される病気
    • がん
  • 欧州デバイス規制

第3章 市場分析

  • 分子ポイントオブケア市場分析
  • 地域別シェア
  • 疾病領域別の内訳
  • 「ベッドサイド分子検査」市場
  • ベッドサイド分子検査のベンダー市場シェア

第4章 企業プロファイル

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMerieux SA
  • Cepheid (Danaher)
  • Credo Diagnostics Biomedical Pte. Ltd.
  • Curetis NV (OpGen)
  • DiaSorin S.p.A
  • GenMark Diagnostics (Roche)
  • Greiner Bio-One GmbH
  • Lucira Health (Pfizer)
  • Meridian Bioscience, Inc. (SD Biosensor)
  • Mesa Biotech, Inc. (Thermo)
  • QIAGEN NV
  • QuantuMDx Group
  • QuidelOrtho Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems
目次
Product Code: 25-018KA

Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information's latest report, "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.

Market Drivers & Opportunities

mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.

With leading companies such as Abbott, Cepheid, bioMerieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:

  • What is the size and projected growth of the mPOC market?
  • Which companies are leading the market, and how are they positioned?
  • How is mPOC impacting traditional laboratory-based molecular testing?
  • What regions and disease segments present the greatest opportunities?

Comprehensive Market Insights

This report offers detailed segmentation of the mPOC market, including:

  • Market Sizing & Forecasts (2024-2029) - Revenue projections by technology, region, and disease area.
  • Competitive Analysis - Market share breakdowns and insights into leading companies.
  • Geographic Trends - Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
  • Technology & Regulatory Landscape - Overview of CLIA-waived and moderate-complexity molecular platforms.

Scope

"Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029" provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.

This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between "true" molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market's growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.

A Decade of mPOC Research Expertise

Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", offers critical insights to help you navigate and capitalize on this fast-growing segment.

Table of Contents

Chapter 1: Executive Summary

  • Figure 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Figure 1-2: Near Patient Molecular Systems Market, 2024-2029 ($ million)
  • Where is Molecular Point-of-Care in 2025?
    • Table 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Molecular Point-of-Care Market Analysis
    • Table 1-2: Molecular Point-of-Care Market Growth, 2024-2029 (%)
    • Figure 1-3: Molecular Point-of-Care Market, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
  • Market Observations
  • "Near-Patient" Molecular Systems Market
    • Table 1-3: Near Patient Molecular Systems Market, 2024-2029 ($ million)
    • Table 1-4: Near Patient Molecular Systems Market Growth, 2024-2029 (%)
    • Table 1-5: mPOC and Near-Patient Market, 2024-2029 ($ million)
    • Figure 1-4: mPOC and Near-Patient Market, 2024-2029 ($ million)
  • Current Trends
  • Molecular Point-of-Care Diagnostics Defined
  • Usage of Molecular Point-of-Care
  • Leading mPOC Platforms
    • Table 1-6: Molecular POC Diagnostic Platforms and Technologies
  • Trends
  • Scope and Methodology

Chapter 2: Molecular Point-of-Care Market Development and Trends

  • COVID-19 and Molecular POC
    • Table 2-1: Molecular POC COVID-19 Emergency Authorizations
    • CDC Initial Response, Long Term Situation
    • COVID-19's Unique Challenge
    • BARDA Directs Funding to mPOC
  • Regulatory Developments
  • Consortia, Funding, Prizes
  • Deals
    • Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2025
  • Advantages and Disadvantages of Molecular Point-of-Care
    • Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
  • Justification: The Sensitivity/Specificity Argument
  • New Systems and Menu Expansion
    • New Systems Introduced in Development
    • Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
    • STI Continues to Be a Growth Area
  • Deals, Investment in mPOC Systems
    • Roche Acquires LumiraDx for up to $350 Million
    • Thermo Acquires Mesa Biotech
  • China as a POC Market
  • Common Tests and Analytes in POC Diagnostics
  • Component Technologies of Molecular Point-of-Care Diagnostics
    • Microfluidics
    • qPCR
    • Microarrays
    • Isothermal Amplification
    • Test Automation
    • Primers and Probes
    • Detection
    • Next-Generation Sequencing
    • Molecular Diagnostics
    • Real-Time PCR (qPCR)
    • Isothermal Amplification Methods
    • Loop-Mediated Isothermal Amplification (LAMP)
    • Nicking Enzyme Amplification Reaction (NEAR)
    • Strand Displacement Amplification (SDA)
    • Helicase Dependent Amplification (HDA)
    • Nucleic Acid Sequence-Based Amplification (NASBA)
    • Transcription-Mediated Amplification (TMA)
    • Cross Priming Amplification (CPA)
    • Line Probe Assays
  • Applications and Potential Applications for Molecular Point-of-Care
    • Major Testing Applications for Molecular POC Diagnostics
    • Influenza
    • Reclassification of RIDTs
    • Hospital-Acquired Infections (HAIs)
    • Strep A
    • Respiratory Syncytial Virus (RSV)
    • Emerging Applications
    • Zika
    • Other Respiratory Infections
    • Group B Streptococcus
    • Human Papillomavirus
    • Herpes Simplex Virus
    • Vaginitis
    • Tuberculosis
    • Malaria
    • Other Tropical and Neglected Diseases
    • Cancer
  • European Device Regulations

Chapter 3: Market Analysis

  • Molecular Point-of-Care Market Analysis
    • Table 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
    • Figure 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Regional Shares
    • Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
    • Figure 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
    • Figure 3-3: Global Molecular Point-of-Care Market Share, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
  • Breakout by Disease Area
    • Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
    • Figure 3-4: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
    • Figure 3-5: Breakout of Molecular Point-of-Care Market Share, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
  • "Near Patient Molecular" Market
    • Table 3-4: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
    • Figure 3-6: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Vendor Market Share for Near Patient Molecular Testing
    • Table 3-5: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMerieux, Cepheid, Roche, Other]
    • Figure 3-7: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMerieux, Cepheid, Roche, Other]

Chapter 4: Company Profiles

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMerieux SA
    • Table 4-1: bioMerieux FilmArray Est. Systems per Quarter, Q4 '18-Q4 '24
    • Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q4 2024
  • Cepheid (Danaher)
    • Molecular Healthcare-Acquired Infection (HAI) Testing
    • Molecular Sexual Health and Women's Health Testing
    • Molecular Critical Infectious Disease Testing
    • Molecular Oncology/Genetics Testing
  • Credo Diagnostics Biomedical Pte. Ltd.
  • Curetis NV (OpGen)
  • DiaSorin S.p.A
  • GenMark Diagnostics (Roche)
  • Greiner Bio-One GmbH
  • Lucira Health (Pfizer)
  • Meridian Bioscience, Inc. (SD Biosensor)
  • Mesa Biotech, Inc. (Thermo)
  • QIAGEN NV
  • QuantuMDx Group
  • QuidelOrtho Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems